Actively Recruiting
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Led by University of Michigan Rogel Cancer Center · Updated on 2026-01-29
100
Participants Needed
6
Research Sites
292 weeks
Total Duration
On this page
Sponsors
U
University of Michigan Rogel Cancer Center
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
CONDITIONS
Official Title
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent and HIPAA authorization before registration
- ECOG performance status of 0 to 2
- Histologically confirmed diagnosis of any listed peripheral or cutaneous T-cell lymphoma subtype
- Relapsed or refractory disease as defined in the protocol
- Adequate organ and blood function as detailed in the protocol
- Availability of sufficient archival tissue or fresh biopsy tissue as required
- HIV-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months
- Patients with controlled hepatitis B or cured/controlled hepatitis C virus infection
- Ability to take oral medication without crushing, dissolving, or chewing tablets
- Anticipated life expectancy of at least 3 months and ability to comply with study requirements
You will not qualify if you...
- History of or current serious illness or laboratory abnormality that could affect study conduct
- Pregnant or breastfeeding women
- Unwillingness or inability to use effective contraception during and after treatment
- Uncontrolled infections requiring intravenous antibiotics
- Symptomatic congestive heart failure or ejection fraction below 45%
- Unstable angina, unstable cardiac arrhythmia, recent heart attack, stroke, or intracranial hemorrhage within 6 months
- Moderate to severe liver impairment
- Psychiatric or social conditions limiting study compliance
- Major surgery within 21 days before starting therapy
- Less than 14 days since last radiation or chemotherapy or insufficient recovery from treatment toxicities
- Use of systemic steroids above prednisone 10 mg/day
- Prior treatment with pacritinib
- Use of medications increasing bleeding risk except low-dose aspirin
- History of significant bleeding or bleeding disorders within past 3 months
- Allergy to pacritinib or related compounds
- Treatment with strong CYP3A4 inducers or inhibitors without appropriate washout
- Uncontrolled diarrhea or gastrointestinal/metabolic conditions affecting oral drug absorption
- Prior allogeneic stem-cell transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
2
Moffitt Cancer Center
Tampa, Florida, United States, 33612
Not Yet Recruiting
3
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
4
Duke Cancer Institute
Durham, North Carolina, United States, 27710
Actively Recruiting
5
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43202
Actively Recruiting
6
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
Not Yet Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here